- Trials with a EudraCT protocol (45)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
45 result(s) found for: Agenesis.
Displaying page 1 of 3.
EudraCT Number: 2014-002710-23 | Sponsor Protocol Number: P140203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005166-12 | Sponsor Protocol Number: HMPL-004-US-02 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Hutchison MediPharma Enterprises Limited | |||||||||||||
Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine | |||||||||||||
Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003710-13 | Sponsor Protocol Number: Pro-Tac | Start Date*: Information not available in EudraCT |
Sponsor Name:University Hospital Essen | ||
Full Title: A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation | ||
Medical condition: Caucasian paediatric kidney transplant recipients | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003413-35 | Sponsor Protocol Number: WN42349 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) | |||||||||||||
Medical condition: Neuromyelitis Optic Spectrum Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Ongoing) BG (Ongoing) PL (Ongoing) IT (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003365-34 | Sponsor Protocol Number: I4V-MC-JAIV | Start Date*: 2019-05-02 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadeq... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000087-15 | Sponsor Protocol Number: CRd | Start Date*: 2012-03-30 |
Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS | ||
Full Title: A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE... | ||
Medical condition: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000014-38 | Sponsor Protocol Number: THX-G18-001 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Therapix Biosciences Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”) | |||||||||||||
Medical condition: Tourette Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000287-34 | Sponsor Protocol Number: ARO-012 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Arog Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. | |||||||||||||
Medical condition: Advanced or metastatic gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007698-22 | Sponsor Protocol Number: R2-CHOP | Start Date*: 2008-07-10 |
Sponsor Name:GELARC | ||
Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA | ||
Medical condition: B cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003372-37 | Sponsor Protocol Number: ET11-072 | Start Date*: 2014-06-04 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre... | |||||||||||||
Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001188-58 | Sponsor Protocol Number: IDIT001 | Start Date*: 2022-02-16 |
Sponsor Name:Göteborgs Universitet | ||
Full Title: The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial | ||
Medical condition: Type 1 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000394-36 | Sponsor Protocol Number: M17-05-LCZ-ARNI | Start Date*: 2017-12-20 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients | |||||||||||||
Medical condition: Chronic heart failure with reduced left ventricular ejection fraction (NYHA II-III) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001936-86 | Sponsor Protocol Number: COMET | Start Date*: 2020-10-19 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19 | |||||||||||||
Medical condition: Hospitalized patients with mild SARS-CoV-2 infection (WHO R&D Blueprint Ordinal Scale for Clinical Improvement = 3 or 4) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005101-39 | Sponsor Protocol Number: ORION-LVAD-1 | Start Date*: 2018-06-06 | ||||||||||||||||
Sponsor Name:Hannover Medical School | ||||||||||||||||||
Full Title: A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with heart failure carrying Left Ventricular Assist Devices (ORION-LVA... | ||||||||||||||||||
Medical condition: Patients with iron deficiency anemia and heart failure carrying left ventricular assist devices (LVAD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000564-42 | Sponsor Protocol Number: CANNA-TICS | Start Date*: 2017-06-14 | ||||||||||||||||
Sponsor Name:Hannover Medical School | ||||||||||||||||||
Full Title: A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS) | ||||||||||||||||||
Medical condition: Chronic tic disorders and Tourette syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004495-60 | Sponsor Protocol Number: I4V-MC-JAHU | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit... | |||||||||||||
Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004422-29 | Sponsor Protocol Number: I8F-MC-GPGL(b) | Start Date*: 2019-07-26 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2) | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000119-10 | Sponsor Protocol Number: I4V-MC-JAHW | Start Date*: 2019-08-06 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Ch... | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis Associated Uveitis or Anterior Antinuclear Antibody-Positive Uveitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000780-24 | Sponsor Protocol Number: MOR202C103 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:MorphoSys AG | |||||||||||||
Full Title: A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE | |||||||||||||
Medical condition: Primary (anti-PLA2R antibody positive) Membranous Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Completed) BE (Completed) FR (Ongoing) IT (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005100-26 | Sponsor Protocol Number: ORION-PH-1 | Start Date*: 2017-10-09 | ||||||||||||||||
Sponsor Name:Hannover Medical School | ||||||||||||||||||
Full Title: A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency an... | ||||||||||||||||||
Medical condition: Patients with iron deficiency anemia and pulmonary hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.